Literature DB >> 17228864

Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.

Mark Froimowitz1, Yonghong Gu, Les A Dakin, Pamela M Nagafuji, Charles J Kelley, Damon Parrish, Jeffrey R Deschamps, Aaron Janowsky.   

Abstract

Methylphenidate analogues, in which the carbomethoxy has been replaced by an alkyl group and with different phenyl substituents, have been synthesized and tested in monoamine transporter assays. As predicted from a pharmacophore model, most of the RR/SS diastereomers showed high potency as dopamine reuptake inhibitors. Analogues with a 4-chlorophenyl group and an unbranched initial alkyl atom had consistently enhanced selectivity for the dopamine transporter. The most potent compounds were those with a three- or four-carbon chain. The "inactive" RS/SR diastereomers showed substantial activity when the phenyl substituent was 3,4-dichloro. On a locomotor assay, one compound was found to have a slow onset and a long duration of action. The activity of these compounds provides additional evidence for a conformational/superposition model of methylphenidate with cocaine-like structures. A ketone analogue, obtained by hydrogenating a previously described vinylogous amide, had activity similar to that of methylphenidate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17228864     DOI: 10.1021/jm0608614

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

2.  Computational modeling of human dopamine transporter structures, mechanism and its interaction with HIV-1 transactivator of transcription.

Authors:  Yaxia Yuan; Xiaoqin Huang; Jun Zhu; Chang-Guo Zhan
Journal:  Future Med Chem       Date:  2016-10-14       Impact factor: 3.808

3.  Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.

Authors:  David J Lapinsky; Ranganadh Velagaleti; Nageswari Yarravarapu; Yi Liu; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Rejwi Acharya; Roxanne A Vaughan; Howard M Deutsch
Journal:  Bioorg Med Chem       Date:  2010-11-04       Impact factor: 3.641

4.  CTDP-32476: A Promising Agonist Therapy for Treatment of Cocaine Addiction.

Authors:  Zheng-Xiong Xi; Rui Song; Xia Li; Guan-Yi Lu; Xiao-Qing Peng; Yi He; Guo-Hua Bi; Siyuan Peter Sheng; Hong-Ju Yang; Haiying Zhang; Jin Li; Mark Froimowitz; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2016-08-18       Impact factor: 7.853

5.  Low and high affinity dopamine transporter inhibitors block dopamine uptake within 5 sec of intravenous injection.

Authors:  J T Yorgason; S R Jones; R A España
Journal:  Neuroscience       Date:  2011-03-21       Impact factor: 3.590

6.  Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin? Implication for anti-addiction medications.

Authors:  Xiao-Qing Peng; Zheng-Xiong Xi; Xia Li; Krista Spiller; Jie Li; Lauren Chun; Kuo-Ming Wu; Mark Froimowitz; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2010-09-08       Impact factor: 7.853

Review 7.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

8.  Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (±)-threo-Methylphenidate.

Authors:  David J Lapinsky; Nageswari Yarravarapu; Tammy L Nolan; Christopher K Surratt; John R Lever; Michael Tomlinson; Roxanne A Vaughan; Howard M Deutsch
Journal:  ACS Med Chem Lett       Date:  2012-03-11       Impact factor: 4.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.